New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19

We report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These patients had been stable for a median period of six years, with no evidence of disease activity and no...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoso, Yara D, Gomes, Sidney, Gonçalves, Marcus Vinicius M, Mendes Junior, Euldes, Oliveira, Bianca Etelvina S de, Rocha, Cristiane Franklin, Santos, Gutemberg A Cruz dos, Tauil, Carlos Bernardo, Araujo, Raquel Vassao, Peron, Jean Pierre S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511887/
https://www.ncbi.nlm.nih.gov/pubmed/35158439
http://dx.doi.org/10.1016/j.msard.2021.103321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511887/
https://www.ncbi.nlm.nih.gov/pubmed/35158439
http://dx.doi.org/10.1016/j.msard.2021.103321

Ejemplares similares